2002
No association between a single nucleotide polymorphism in CYP19 and breast cancer risk.
Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiology Biomarkers & Prevention 2002, 11: 215-6. PMID: 11867511.Peer-Reviewed Original Research
2000
A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk
Haiman C, Hankinson S, Spiegelman D, De Vivo I, Colditz G, Willett W, Speizer F, Hunter D. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. International Journal Of Cancer 2000, 87: 204-210. PMID: 10861475, DOI: 10.1002/1097-0215(20000715)87:2<204::aid-ijc8>3.0.co;2-3.Peer-Reviewed Original ResearchConceptsBreast cancer riskHealth Study cohortCase-control studyCancer riskHormone levelsNurses' Health Study cohortBreast cancer case-control studyElevated estrogen levelsAdvanced cancer casesCancer case-control studyRepeat polymorphismTetranucleotide repeat polymorphismConversion of androgensGreater frequencyKey steroidogenic enzymesSignificant greater frequencyDistant metastasisStudy cohortEstrogen levelsCYP19 allelesBreast cancerCancer casesAllele carriersEstrone sulfateNonsignificant increase